Physician profile
Ariel Martinez
NPI 1831262880
$3,115.97
in general payments reported to CMS, 2019-2025
21 companies · $260 in 2025
The $260 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $686 · 2020: $414 · 2021: $415 · 2022: $334 · 2023: $547 · 2024: $458 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,266.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $677.98 | 2019-2021 | |
| Glaxosmithkline, LLC. | $677.49 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Abbott Laboratories | $674.75 | 2022-2025 | Freestyle Libre 3 |
| Pfizer INC. | $228.41 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.73 | 2020-2024 | Jardiance |
| Lilly USA, LLC | $146.31 | 2022-2023 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $125.67 | 2019-2024 | Breztri, Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $50.45 | 2019 | |
| Phathom Pharmaceuticals, INC. | $44.21 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $44.17 | 2019-2020 | |
| Daiichi Sankyo INC. | $43.30 | 2019-2020 | |
| Amgen INC. | $41.42 | 2020-2024 | Otezla, Repatha |
| Exact Sciences Corporation | $28.38 | 2025 | Cologuard Collection Kit |
| Csl Behring | $28.00 | 2025 | Hizentra |
| E.R. Squibb & Sons, L.L.C. | $23.85 | 2025 | Eliquis |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $22.60 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.32 | 2025 | |
| Abbvie INC. | $19.28 | 2021 | |
| Sunovion Pharmaceuticals INC. | $18.95 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.97 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ariel Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.